CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-08-26): Elispot assay: a promising substitute for tuberculin skin test for latent TB

Clinical

Elispot assay: a promising substitute for tuberculin skin test for latent TB

Last Updated: 2008-08-26 8:30:44 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Elispot, an enzyme-linked immunospot assay that detects Mycobacterium tuberculosis antigens, is a useful screening test to rule out latent tuberculosis infection in rheumatic disease patients starting treatment with a tumor necrosis factor antagonist, according to physicians in Greece.

Because it is not affected by previous bacillus Calmette-Guerin vaccination or immunosuppression, Elispot may be preferable to the tuberculin skin test in such patients, Dr. Dimitrios Vassilopoulos and his associates at the Athens University School of Medicine report in the July issue of the Journal of Rheumatology.

The research team compared tuberculin skin test and Elispot results in 70 patients with various rheumatic diseases. Discordant results were obtained for 15 patients (21%) who were Elispot-negative/tuberculin skin test-positive and 4 (6%) who were Elispot-positive/tuberculin skin test-negative.

In multivariate analysis, a history of bacillus Calmette-Guerin vaccination was associated with Elispot-negative/tuberculin skin test-positive discordant results, and steroid use was associated with Elispot-positive/tuberculin skin test-negative results.

The frequency of Elispot-negative/tuberculin skin test-positive discordancy suggests a high rate of potentially unnecessary exposure to isoniazid prophylaxis, the authors maintain.

"This is particularly important," they explain, "because isoniazid-related liver toxicity may be even higher in rheumatic patients who, especially with rheumatoid arthritis, are being treated with other potentially hepatotoxic medications such as methotrexate, nonsteroidal antiinflammatory drugs, leflunomide, sulfasalazine, etc."

On the other hand, spotting steroid-treated patients with negative tuberculin skin test results and positive Elispot results could lead to appropriate initiation of prophylactic treatment.

Still, the Greek research team does not at this time advocate replacing the tuberculin skin test with the Elispot assay.

They conclude: "More data examining the test's cost, feasibility, and reproducibility, as well as the outcome of anti-TNF-treated rheumatic patients with discordant tuberculin skin test/Elispot results, are needed before evidence-based recommendations can be made."

J Rheumatol 2008;35:1271-1276.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.